Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;34(4):952-966.
doi: 10.1177/11206721231219532. Epub 2023 Dec 12.

Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute

Affiliations
Review

Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute

Beáta Tapasztó et al. Eur J Ophthalmol. 2024 Jul.

Abstract

Myopia is becoming increasingly common in young generations all over the world, and it is predicted to become the most common cause of blindness and visual impairment in later life in the near future. Because myopia can cause serious complications and vision loss, it is critical to create and prescribe effective myopia treatment solutions that can help prevent or delay the onset and progression of myopia. The scientific understanding of myopia's causes, genetic background, environmental conditions, and various management techniques, including therapies to prevent or postpone its development and slow its progression, is rapidly expanding. However, some significant information gaps exist on this subject, making it difficult to develop an effective intervention plan. As with the creation of this present algorithm, a compromise is to work on best practices and reach consensus among a wide number of specialists. The quick rise in information regarding myopia management may be difficult for the busy eye care provider, but it necessitates a continuing need to evaluate new research and implement it into daily practice. To assist eye care providers in developing these strategies, an algorithm has been proposed that covers all aspects of myopia mitigation and management. The algorithm aims to provide practical assistance in choosing and developing an effective myopia management strategy tailored to the individual child. It incorporates the latest research findings and covers a wide range of modalities, from primary, secondary, and tertiary myopia prevention to interventions that reduce the progression of myopia.

Keywords: Myopia; atropine; management algorithm; myopia control interventions; orthokeratology; pre-myopia; preventive medicine; screening; time spent outdoors.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JBJ discloses European patent EP 3 271 392, JP 2021-119187, and US 2021 0340237 A1: „Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia”; AG discloses grants from Alcon, Bausch&Lomb, Zeiss, Teleon, J&J, CooperVision, Hoya, Essilor, Thea, Polpharma, Viatris, consultation: Polpharma, Eyerising, lectures: Thea, Polpharma, Viatris, member of Advisory Boards: Nevakar, GoCheckKids and Thea; JAG discloses editorial board memberships: IOVS, TVST, OPO, grants panel: Fight for Sight UK, consultant for several companies, however the consultancy fee is paid directly by the company to an eye research charity chosen by the company; RCB discloses editorial board memberships: Investigative Ophthalmology and Visual Science (IOVS), Current Eye Research, Scandinavian Journal of Optometry and Visual Science (SJOVS). JRP discloses consultant: Essilor, Hoya, Sightglass, Vyluma, Government funding by ZonMw; JSW discloses consultant: Alcon, Allergan, AOS, Bausch & Lomb, CooperVision, CSIDryEye, DopaVision, M2C Pharmaceuticals, Medmont, Novartis, NuVision, Santen, Scope Ophthalmics, SightGlass, Théa, shares in AstonVision Sciences, Eyoto, Wolffsohn Research Limited, and funding by Alcon, Allergan, Johnson & Johnson Vision, Rayner, M2C Pharmaceuticals, Novartis, NuVision, Scope Ophthalmics, SightGlass, Théa, Topcon, The Eye Doctor; SW is employee of Carl Zeiss Vision International GmbH; SR discloses consultant: BHVI (C), Thea (C); DIF discloses trial support from CooperVision, Topcon and Vyluma Inc., consultant: Coopervision, Thea, Vyluma, EssilorLuxottica, Sightglass, Johnson and Johnson, and commercial interest in Ocumetra Ltd.KJS is in receipt of research funding from Hoya Vision and Vyluma Inc; SJM Is in receipt of research funding from Hoya Vision; HK is consultant for Hoya and Haag-Streit. The other authors declared no potential conflicts of interest with respect to the authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Initial refractive assessment flowchart. Algorithm for the primary and secondary prevention of myopia. Numbers refer to the stages identified in the text. The flowchart needs to be read from top to bottom, however at some decision points, certain responses are going upward and eventually returning to an earlier level of the flowchart, showing the necessity for repeated cycles to monitor and follow-up on myopia development and intervention procedures. (D: diopter, SER: spherical equivalent refraction).
Figure 2.
Figure 2.
Treatment flowchart. Algorithm for reducing myopia progression. (Ortho-K: orthokeratology, SER: spherical equivalent refraction).

References

    1. Németh J, Tapasztó B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol 2021; 31: 853–883. - PMC - PubMed
    1. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci 2021; 62: 6. - PMC - PubMed
    1. Bullimore MA, Brennan NA, Flitcroft DI. The future of clinical trials of myopia control. Ophthalmic Physiol Opt 2023; 43: 525–533. - PubMed
    1. Jones L, Drobe B, González-Méijome JM, et al. IMI - industry guidelines and ethical considerations for myopia control report. Invest Ophthalmol Vis Sci 2019; 60: M161–M183. - PubMed
    1. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond) 2019; 33: 3–13. - PMC - PubMed

LinkOut - more resources